These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 33469316)

  • 1. Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study.
    Corren J; Karpefors M; Hellqvist Å; Parnes JR; Colice G
    J Asthma Allergy; 2021; 14():1-11. PubMed ID: 33469316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with and without Nasal Polyposis: A
    Emson C; Corren J; Sałapa K; Hellqvist Å; Parnes JR; Colice G
    J Asthma Allergy; 2021; 14():91-99. PubMed ID: 33568920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR).
    Pavord ID; Hoyte FCL; Lindsley AW; Ambrose CS; Spahn JD; Roseti SL; Cook B; Griffiths JM; Hellqvist Å; Martin N; Llanos JP; Martin N; Colice G; Corren J
    Ann Allergy Asthma Immunol; 2023 Nov; 131(5):587-597.e3. PubMed ID: 37619779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma and Perennial Allergy.
    Corren J; Ambrose CS; Sałapa K; Roseti SL; Griffiths JM; Parnes JR; Colice G
    J Allergy Clin Immunol Pract; 2021 Dec; 9(12):4334-4342.e6. PubMed ID: 34358701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials.
    Corren J; Menzies-Gow A; Chupp G; Israel E; Korn S; Cook B; Ambrose CS; Hellqvist Å; Roseti SL; Molfino NA; Llanos JP; Martin N; Bowen K; Griffiths JM; Parnes JR; Colice G
    Am J Respir Crit Care Med; 2023 Jul; 208(1):13-24. PubMed ID: 37015033
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial.
    Diver S; Khalfaoui L; Emson C; Wenzel SE; Menzies-Gow A; Wechsler ME; Johnston J; Molfino N; Parnes JR; Megally A; Colice G; Brightling CE;
    Lancet Respir Med; 2021 Nov; 9(11):1299-1312. PubMed ID: 34256031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma.
    Menzies-Gow A; Colice G; Griffiths JM; Almqvist G; Ponnarambil S; Kaur P; Ruberto G; Bowen K; Hellqvist Å; Mo M; Garcia Gil E
    Respir Res; 2020 Oct; 21(1):266. PubMed ID: 33050934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline type 2 biomarker levels and response to tezepelumab in severe asthma.
    Corren J; Pham TH; Garcia Gil E; Sałapa K; Ren P; Parnes JR; Colice G; Griffiths JM
    Allergy; 2022 Jun; 77(6):1786-1796. PubMed ID: 34913186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?
    Menzies-Gow A; Wechsler ME; Brightling CE
    Respir Res; 2020 Oct; 21(1):268. PubMed ID: 33059715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tezepelumab in Adults with Uncontrolled Asthma.
    Corren J; Parnes JR; Wang L; Mo M; Roseti SL; Griffiths JM; van der Merwe R
    N Engl J Med; 2017 Sep; 377(10):936-946. PubMed ID: 28877011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study.
    Carr TF; Moore WC; Kraft M; Brusselle G; Castro M; Chupp GL; Wechsler ME; Hunter G; Lindsley AW; Llanos JP; Burke LK; Chandarana S; Ambrose CS
    Adv Ther; 2024 Jul; 41(7):2978-2990. PubMed ID: 38802635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR.
    Laidlaw TM; Menzies-Gow A; Caveney S; Han JK; Martin N; Israel E; Lee JK; Llanos JP; Martin N; Megally A; Parikh B; Vong S; Welte T; Corren J
    J Asthma Allergy; 2023; 16():915-932. PubMed ID: 37692126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma.
    Wechsler ME; Colice G; Griffiths JM; Almqvist G; Skärby T; Piechowiak T; Kaur P; Bowen K; Hellqvist Å; Mo M; Garcia Gil E
    Respir Res; 2020 Oct; 21(1):264. PubMed ID: 33050928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.
    Menzies-Gow A; Corren J; Bourdin A; Chupp G; Israel E; Wechsler ME; Brightling CE; Griffiths JM; Hellqvist Å; Bowen K; Kaur P; Almqvist G; Ponnarambil S; Colice G
    N Engl J Med; 2021 May; 384(19):1800-1809. PubMed ID: 33979488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma.
    Emson C; Diver S; Chachi L; Megally A; Small C; Downie J; Parnes JR; Bowen K; Colice G; Brightling CE
    Respir Res; 2020 Oct; 21(1):265. PubMed ID: 33050900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of tezepelumab in patients recruited in Japan who participated in the phase 3 NAVIGATOR study.
    Ishizuka T; Menzies-Gow A; Okada H; Fukushima Y; Hayashi N; Colice G; Ponnarambil S; Hunter G; Odajima H; Ebisawa M
    Allergol Int; 2023 Jan; 72(1):82-88. PubMed ID: 35977863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study.
    Menzies-Gow A; Wechsler ME; Brightling CE; Korn S; Corren J; Israel E; Chupp G; Bednarczyk A; Ponnarambil S; Caveney S; Almqvist G; Gołąbek M; Simonsson L; Lawson K; Bowen K; Colice G;
    Lancet Respir Med; 2023 May; 11(5):425-438. PubMed ID: 36702146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of tezepelumab in patients with evidence of severe allergic asthma: Results from the phase 3 NAVIGATOR study.
    Corren J; Ambrose CS; Griffiths JM; Hellqvist Å; Lindsley AW; Llanos JP; Colice G; Menzies-Gow A
    Clin Exp Allergy; 2023 Apr; 53(4):417-428. PubMed ID: 36507576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma.
    Menzies-Gow A; Ponnarambil S; Downie J; Bowen K; Hellqvist Å; Colice G
    Respir Res; 2020 Oct; 21(1):279. PubMed ID: 33087119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types.
    Panettieri R; Lugogo N; Corren J; Ambrose CS
    J Asthma Allergy; 2024; 17():219-236. PubMed ID: 38524099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.